Clearmind Medicine Inc.
Business
Clearmind Medicine Inc. is a clinical-stage pharmaceutical company developing novel psychedelic and neuroplastogen therapies aimed at treating mental health disorders, with a primary focus on alcohol use disorder (AUD). It develops the MEAI-based drug candidate CMND-100 and other compounds (including 2‑FDCK and benzofuran derivatives) as prescription therapeutics and an alcohol‑substitute consumer product, backed by preclinical work and Phase I/IIa trials. Key business segments include preclinical research and development, clinical development, and intellectual property and licensing. The company conducts research and clinical trials across the United States, Israel, China and Europe and engages academic, regulatory and clinical channels for development and distribution.
Summary from filing dated 2026-01-20
Financials
Latest annual snapshot (FY2025, period end 2025-10-31). Full statement history unavailable for this entity.
| Revenue | — |
| Net income | — |
| Total assets | $6.08M |
| Total liabilities | $4.89M |
| Stockholders' equity | — |
| Operating cash flow | — |